✦ LIBER ✦

The JAK/STAT pathway in rheumatoid arthritis: Pathogenic or protective?

✍ Scribed by Lionel B. Ivashkiv; Xiaoyu Hu

Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 194 KB
Volume: 48
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.11095

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pathogenic role of the CXCL16–CXCR6 path

Pathogenic role of the CXCL16–CXCR6 pathway in rheumatoid arthritis

✍ Toshihiro Nanki; Takeshi Shimaoka; Kenji Hayashida; Ken Taniguchi; Shin Yonehara 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 352 KB 👁 1 views

Phase IIb dose-ranging study of the oral

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

✍ Roy Fleischmann; Maurizio Cutolo; Mark C. Genovese; Eun Bong Lee; Keith S. Kanik 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 1 views